Scancell shareholders vote at a General Meeting on 20 October 2026 on a debt facility of up to US$25,000,000 from BlackRock-managed funds and a 1-for-10 share consolidation, days after preliminary results flagged a material going-concern uncertainty.
Scancell Holdings plc (LSE:SCLP), the Oxford-based clinical-stage immunotherapy developer, will hold its General Meeting at 11.00 a.m. (London time) on 20 October 2026 at the offices of Cooley (UK) LLP, 22 Bishopsgate, London EC2N 4BQ. Shareholders will vote on the debt facility from funds and accounts managed by BlackRock and on a proposed share consolidation. If approved, the consolidation record date is 6.00 p.m. on 20 October 2026, and admission of the consolidated shares is expected at 8.00 a.m. on 21 October 2026.
The stock is one of the most-discussed UK stocks among investors today. The latest company announcement was the preliminary results for the year ended 30 April 2026, published on 9 October 2026, which disclosed "material uncertainties which may cast significant doubt on the Group's ability to continue as a going concern". There has been no new announcement today. Market data showed that the shares were at 9.35p on 14 October 2026, unchanged on the day, close to the 9 pence price of the July 2026 placing and retail offer.
What shareholders are voting on
The debt facility, announced on 24 September 2026, is worth up to US$25,000,000 and is structured in tranches. The first drawdown of US$7,000,000 is conditional on shareholder approval at the meeting. Key terms include:
- US$8,000,000 available following completion of the US Listing Transactions and the opening of the first Phase 3 clinical site.
- A final tranche available until 31 December 2027, subject to a minimum share fundraising threshold.
- Interest of 10.50% per annum on term tranches, with an 18-month interest-only period.
- Up to US$5,000,000 convertible at a 30% premium to the July 2026 fundraising price.
- Warrants to Kreos Capital VIII Aggregator SCSp.
Dr Phil L'Huillier, CEO, said: "The debt facility is an important part of a share and debt package in conjunction with the planned merger".
The second proposal is a share consolidation of "1 Consolidated Ordinary Share of £0.01 for every 10 Existing Ordinary Shares of £0.001 each". The Notice of GM gave 1,212,230,683 existing shares in issue as at 30 September 2026. The company said the consolidation is not conditional on the US listing transactions.
The Neuphoria merger and Nasdaq plan
Both proposals sit within a wider transaction. On 23 July 2026, Scancell (LSE:SCLP) agreed an all-share merger with Neuphoria Therapeutics Inc. (Nasdaq: NEUP), a Massachusetts-based biotech whose BNC210 programme in social anxiety disorder was halted after its AFFIRM-1 Phase 3 trial missed its endpoints. The combined company is to be named Scancell and to apply for a Nasdaq listing under the symbol "SCLT", in addition to AIM.
Excluding the financing and conversion of convertible loan notes, existing Scancell shareholders would hold 85.5% and Neuphoria shareholders 14.5%. The overall financing package is up to $89 million, including a Private Placement of $39.1 million at $0.1205 (£0.09) per share, the UK offerings and the debt facility. Pro forma net cash is approximately £59.2 million before transaction costs, which the company expects to extend its cash runway into 2029.
Dr L'Huillier said at the time that the board believed the transaction would create near- and long-term value for shareholders of both companies.
The UK Placing was upsized to £13.0 million gross through 144,444,444 shares after being "very significantly oversubscribed", and the combined UK offerings raised £15.7m gross. The Form F-4 was expected to be filed with the SEC on 9 October 2026, and completion of the US Listing Transactions is guided for late Q4 2026.
Results and the going-concern warning
The preliminary results for the year ended 30 April 2026 (unaudited) showed:
- Revenue of nil (FY2025: £4,711k).
- An operating loss of £17,424k (£15,001k).
- A loss before tax of £20,227k (£15,303k).
- A loss for the year of £17,901k (£12,272k).
- Cash and cash equivalents of £5,323k (£16,894k).
- Net liabilities of £19,410k.
The company said "the Group does not currently have sufficient committed funding to meet its forecast cash requirements", although the accounts were still prepared on a going-concern basis. Convertible loan notes had a face value of £18.2m. Redmile has agreed to convert all outstanding notes on completion of the merger; if the merger does not complete, notes fall due in August 2027 (£1.75m) and November 2027 (£16.45m).
The clinical pipeline
The lead asset, iSCIB1+, is being developed for advanced melanoma. It has FDA IND clearance and Fast Track designation for its Phase 3 trial, and MHRA authorisation was announced in August 2026. The trial plans to enrol about 550 patients with Stage IIIB or IV unresectable melanoma, and the start is expected in Q4 2026, with the primary readout expected in H2 2028. The design compares 8 mg iSCIB1+ with ipilimumab and nivolumab against placebo with ipilimumab and nivolumab, and allows for accelerated approval on a statistically significant progression-free survival benefit at the first analysis. A second programme, Modi-1, is being tested in the fully recruited ModiFY trial in head and neck cancer and renal cell carcinoma. The trial has shown partial responses in 3 of 7 head and neck patients, an overall response rate of 43% at 25 weeks, with further data expected later in 2026.
Risks to weigh
Scancell's situation carries several risks:
- Going concern: the material uncertainty is explicit, and funding depends on completing the merger and the private placement.
- Completion: the merger and US listing need shareholder approvals, SEC effectiveness of the F-4 and a Nasdaq listing, with a Merger End Date of 28 February 2027.
- Dilution: the placing, private placement, merger consideration shares, convertible debt and warrants all add shares, and the consolidation will change the share count and quoted price.
- Debt: the facility is secured over substantially all assets, carries a minimum cash requirement and 10.50% interest, and the Redmile notes fall due in 2027 if the merger fails.
- Clinical: the Phase 3 outcome is uncertain, and the primary readout is not expected until H2 2028.
What to watch next
The immediate date is the General Meeting on 20 October 2026, followed by the expected admission of consolidated shares on 21 October 2026. The company has also said its UK Annual Report will be published later in October 2026. After that, investors will be looking for progress on the SEC filing, the Nasdaq listing, the opening of the first Phase 3 site and further ModiFY data. The market capitalisation stands at £126.85m.






Please wait processing your request...